Elicio Therapeutics holds annual shareholder meeting

ELTX•2026-11-13

Elicio Therapeutics held its annual stockholder meeting on November 12, 2026, and stockholders adopted both proposals: electing three directors and ratifying Baker Tilly US as the independent auditor for 2026.

1. Meeting results

Stockholders elected Julian Adams, Jay R. Venkatesan and Carol Ashe to Elicio Therapeutics’ board. They also ratified Baker Tilly US as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Sources

Elicio Therapeutics holds annual shareholder meeting

Sec

Elicio Therapeutics holds annual shareholder meeting

1. Meeting results

Related News

PG&E director Mark E. Ferguson III reports disposal of $114,685.6152 in common shares

Cheetah Net Q3 net loss widens 94% to $2.55 million; revenue rises to $3.56 million

BBB Foods CEO Kamal Anthony Hatoum reports sale of common shares worth $4.1 million

Sources

Elicio Therapeutics holds annual shareholder meeting

Circle Internet Group director Danita K. Ostling reports sale of $97,110 in common shares

Apollo issues $600 million of 7.55% junior subordinated notes due 2056